Home

Mission

The 221b Foundation is committed to equity in science, medicine and society. To address the major crises facing the United States, we are committing to the eradication of COVID-19 and the increased inclusion of underrepresented communities in STEM, specifically focused on racial and gender diversity.

To achieve our mission, The 221b Foundation will provide Sherlock Biosciences’ know-how and intellectual property for its CRISPR platform to any group dedicated to developing COVID-19 testing solutions. Any profits made off of these products, including Sherlock’s own CRISPR COVID-19 test, will be reinvested in STEM programs for women and minority communities.

4 MISSION CRITICAL AREAS


REDUCE

Reduce the threat posed by the COVID-19 virus.

We aim to increase access to Sherlock™ Technology to achieve a 5%* positive testing target per 100,000 people (adjusted for population).

*Note: The WHO has set at 5%. A positivity rate over 5% indicates a state may only be testing the sickest patients who seek out medical care, and are not casting a wide enough net to identify milder cases and track outbreaks.

RECOGNIZE

RECOGNIZE that we must raise awareness about inequality in order to cultivate STEM experts from a diverse range of communities to assist in building the representation necessary to ensure equity of care.

Persistent racial disparities in health status, access to health care, wealth, employment, wages, housing, income, and poverty all contribute to greater susceptibility to the virus—both economically and physically.*

*Source: EPI analysis of Bureau of Labor Statistics Current Population Survey public data.

RECOVER

Recover through supporting these communities and STEM education programs that promote racial and gender diversity.

Profits earned by Sherlock™ technology will fund: K-12 STEM-capable education, building parent education in STEM- career paths, Life Science after-school activities, college prep courses, and community mentorship programs.

REBUILD

Rebuild the post-pandemic workforce of 2030 that will drive the next wave of STEM innovation with a focus on equity and diversity

“To lead in S&E and remain globally competitive in 2030, the U.S. must be a STEM talent powerhouse… Increasing the STEM skills and opportunities for all Americans will require local, state, and federal governments, public and private educational institutions, community organizations, and industry to step up their efforts.”*

*The National Science Board, “Vision 2030”

Call for Support

  • We are advancing conversations with multiple public and non-profit organizations that seek to work through The 221b Foundation to enable COVID test development with CRISPR technology. We seek donor support to seed these organizations and support efforts to expand the testing capacity.
  • All profits from COVID products will be directed to organizations that directly support racial and gender diversity in STEM.
  • These dual efforts allow us to give back to the community in two fundamental ways: increasing testing capacity, which is vital to combating the pandemic and funding organizations that further the cause of diversity in STEM where Women, Black and Latinx workers are significantly under-represented.
  • Join us in our mission and be part of the solution that will drive the next generation of innovation in the life sciences.

OUR BOARD

Rahul Dhanda

Co-founding member of The 221b Foundation

Rahul K Dhanda is a founding member of The 221b Foundation. He is the president and chief executive officer of Sherlock Biosciences. He also serves on the company’s Board of Directors. Most recently, Mr. Dhanda spent 10 years at T2 Biosystems where he helped grow the company from an early-staged, venture-backed startup to a commercial, publicly-traded leader in infectious disease diagnostics where he held the role of senior vice president of corporate development and marketing. At T2 Biosystems, he had an expansive role where he led the company’s strategy, marketing, product management and all corporate deal activity, the latter of which brought over $40 million in funding to the company.

Prior to joining T2 Biosystems, Mr. Dhanda worked in Boston Scientific’s urology division, where he led a team responsible for over $100 million in annual revenue. Prior to Boston Scientific, Mr. Dhanda held a business development role at Interleukin Genetics, where he helped lead the negotiation of the firm’s acquisition by Alticor, Inc. as well as multiple other corporate value-creating deals.

Mr. Dhanda earned his MBA. from MIT’s Sloan School of Management and his B.A. from Wesleyan University. He is a former committee member of the AAAS Committee on Scientific Freedom and Responsibility. Mr. Dhanda is the author of several publications, an inventor on numerous patents, and has authored the first book to address the crossroads between industry and bioethics/public policy, entitled Guiding Icarus: Merging Bioethics with Corporate Interests.

Mark C Jefferson

Co-founding member of The 221b Foundation

Mark C Jefferson is a founding member of The 221b Foundation. He is the assistant dean for Community Engagement and Equity at Harvard Law School. He previously served HLS as director of Community Engagement and Equity and was promoted to assistant dean effective October 30. Prior to joining HLS in 2017, he was the assistant director of admissions at the University of Michigan Law School.

Jefferson holds a J.D. from the University of Michigan Law School, and he graduated magna cum laude from Morehouse College. He also completed graduate coursework at the Boston University School of Theology.

He worked as a lawyer at the law firm of Thelen LLP in New York and at the Public Defender Service for the District of Columbia. He has worked in education as director of alumni support at St. Ignatius Loyola Academy in Baltimore and as the founding dean of students and language arts teacher at the Seed Public Charter School in Washington.

Media Contact: Katie Engleman, 1AB, katie@1abmedia.com

Contact The 221b Foundation